{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-000338","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2023-01-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.358933+00:00","generated_at":"2026-06-20T13:10:29.792499+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Compass Therapeutics reports positive Phase 2 data for CTX-009 in biliary tract cancers; ORR 37.5%","bullets":["CTX-009 + paclitaxel achieved 37.5% ORR in 24 patients; second-line sub-group ORR 63.6% (7/11 PRs).","Median PFS 9.4 months, median OS 12.5 months; data to be presented at ASCO GI on Jan 20, 2023.","Randomized Phase 2/3 trial (up to 150 patients) initiated in US; may enable BLA submission in H2 2024.","Safety consistent with prior studies; Grade 3+ TEAEs included decreased neutrophils (83.3%), hypertension (16.7%).","Investor webcast scheduled for Jan 23 at 8:30am ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-000338","json":"https://secwatch.observer/filing/0001171843-23-000338.json","markdown":"https://secwatch.observer/filing/0001171843-23-000338.md","text":"https://secwatch.observer/filing/0001171843-23-000338.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323000338/0001171843-23-000338-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323000338/f8k_011923.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T13:10:29.792499+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}